The Vielight 655 is a laser intranasal photobiomodulation device. The laser beam footprint targets the nasal cavity, which is rich in blood capillaries. The device parameters have been derived from researching clinical studies on low level light therapy over the last few decades. Although many researchers now believe that the outcomes between low level laser and the non-laser light emitting diodes (LED) to be similar, the laser light should penetrate deeper into the tissues.
This is the laser equivalent of the 633 Red device.
This device utilizes a low level (or “cold”) laser diode to release coherent light in the visible red spectrum (655 nm), powered by a calculated dosage of energy to irradiate the capillary-rich nasal cavity. The energy generated by this version is lower than the 633 Red resulting in a more power-efficient design.
Our intranasal devices combine solid state technology along with intranasal diodes built from transparent high impact polycarbonate to ensure quality and durability, turning this into a lifetime investment.
Description
The Vielight 655 emits low level laser light with a 655 nm wavelength. The light pulses continuously with a power density of 5 mw/cm2.
The laser beam footprint targets the nasal cavity, which is rich in blood capillaries. The device parameters have been derived from researching clinical studies on low level light therapy over the last few decades. Although many researchers now believe that the outcomes between low level laser and the non-laser light emitting diodes (LED) to be similar, the laser light should penetrate deeper into the tissues.
As a safety measure, please do not look into the laser light source.
- Vielight 655 User Guide | Link.
Warranty: One-year manufacturer’s warranty
Please note that this product comes with an intranasal applicator
Brand | |
---|---|
Storage Instructions | Store unplugged |
Disclaimer | Please follow unit instructions carefully. Vielight products are sold without any claims of efficacy or results. |
Barcode |
Reviews
There are no reviews yet.